[go: up one dir, main page]

UY31769A1 - Derivados del indol con actividad modulatoria del receptor nicotínico de acetilcolina - Google Patents

Derivados del indol con actividad modulatoria del receptor nicotínico de acetilcolina

Info

Publication number
UY31769A1
UY31769A1 UY031769A UY31769A UY31769A1 UY 31769 A1 UY31769 A1 UY 31769A1 UY 031769 A UY031769 A UY 031769A UY 31769 A UY31769 A UY 31769A UY 31769 A1 UY31769 A1 UY 31769A1
Authority
UY
Uruguay
Prior art keywords
nicotinic
acetilcoline
indol
derivatives
receiver
Prior art date
Application number
UY031769A
Other languages
English (en)
Inventor
Howard Robert Marshall
Andrew P Lightfoot
Kevin Dinnell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0807050A external-priority patent/GB0807050D0/en
Priority claimed from GB0810229A external-priority patent/GB0810229D0/en
Application filed filed Critical
Publication of UY31769A1 publication Critical patent/UY31769A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se refiere a la modulación del receptor nicotínico de acetilcolina (nAChR) a7 por un compuesto de fórmula (I) o una sal del mismo:
UY031769A 2008-04-17 2009-04-16 Derivados del indol con actividad modulatoria del receptor nicotínico de acetilcolina UY31769A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0807050A GB0807050D0 (en) 2008-04-17 2008-04-17 Novel compounds
GB0810229A GB0810229D0 (en) 2008-06-04 2008-06-04 Novel compounds

Publications (1)

Publication Number Publication Date
UY31769A1 true UY31769A1 (es) 2009-09-30

Family

ID=40791353

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031769A UY31769A1 (es) 2008-04-17 2009-04-16 Derivados del indol con actividad modulatoria del receptor nicotínico de acetilcolina

Country Status (19)

Country Link
US (2) US8283365B2 (es)
EP (2) EP2279184B1 (es)
JP (2) JP2011516598A (es)
KR (2) KR20100135911A (es)
CN (2) CN102066356B (es)
AR (1) AR071203A1 (es)
AU (2) AU2009237650B2 (es)
BR (2) BRPI0911682A2 (es)
CA (2) CA2721630A1 (es)
CL (1) CL2009000916A1 (es)
EA (2) EA018113B1 (es)
ES (2) ES2392795T3 (es)
IL (2) IL208575A (es)
MX (2) MX2010011359A (es)
PE (1) PE20091724A1 (es)
TW (1) TW201004939A (es)
UY (1) UY31769A1 (es)
WO (2) WO2009127679A1 (es)
ZA (2) ZA201006855B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
JP2011500625A (ja) 2007-10-18 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリ置換された１，２，４−トリアゾール
WO2009097306A1 (en) * 2008-01-30 2009-08-06 Cephalon, Inc. Substituted pyridazine derivatives which have histamine h3 antagonist activity
NZ587669A (en) 2008-03-19 2011-07-29 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
EP2280945B1 (en) 2008-05-09 2014-09-03 Janssen Pharmaceutica, N.V. Trisubstituted pyrazoles as acetylcholine receptor modulators
KR20120089190A (ko) * 2009-04-16 2012-08-09 프록시머겐 리미티드 알파 7 니코틴 아세틸콜린 수용체(ｎＡＣｈＲ)의 인돌 유도체 조절체
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
GB201012686D0 (en) * 2010-07-28 2010-09-15 Glaxo Group Ltd Novel compounds
JO3078B1 (ar) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
US20130310419A1 (en) 2011-02-03 2013-11-21 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
MA34957B1 (fr) 2011-02-23 2014-03-01 Lupin Ltd Derives heteroaryle a titre modulateurs des nachr alpha 7
MX2013010698A (es) * 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
EP2691368A1 (en) 2011-03-31 2014-02-05 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
TW201245185A (en) 2011-04-01 2012-11-16 Lundbeck & Co As H New positive allosteric modulators of nicotinic acetylcholine receptor
US8946432B2 (en) 2011-07-05 2015-02-03 Lupin Limited Biaryl derivatives as nAChR modulators
EP2822946A1 (en) 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
KR20150008891A (ko) * 2012-05-08 2015-01-23 앤빌 엘엘씨 알파 7 니코틴성 아세틸콜린 수용기 알로스테릭 조절제, 그의 유도체 및 그의 용도
HK1209115A1 (en) * 2012-10-02 2016-03-24 Sumitomo Dainippon Pharma Co., Ltd. Imidazole derivative
EP2945936A1 (en) 2012-11-12 2015-11-25 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
CN103006642B (zh) * 2013-01-04 2014-10-22 中国药科大学 一类炔亚甲基吲哚-2-酮类衍生物的用途
EP2945941B1 (en) 2013-01-16 2016-12-07 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
JP2016512225A (ja) 2013-03-13 2016-04-25 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ アルファー７ｎａｃｈｒモジュレータとしてのピロール誘導体
US10058310B2 (en) 2013-03-13 2018-08-28 Ethicon Llc Electrosurgical device with drum-driven articulation
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
EP3122187A4 (en) * 2014-03-25 2017-11-15 Emicipi LLC Treatment of rett syndrome
JP6870304B2 (ja) * 2016-12-05 2021-05-12 住友電気工業株式会社 半導体装置の製造方法
US11046683B2 (en) 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
AU2020394867A1 (en) 2019-12-02 2022-05-26 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors
CN111285792B (zh) * 2020-03-23 2023-05-02 三峡大学 2-取代吲哚化合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903997D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
KR20100124272A (ko) * 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법

Also Published As

Publication number Publication date
EA018113B1 (ru) 2013-05-30
CN102066356B (zh) 2014-06-11
EA201071202A1 (ru) 2011-06-30
JP2011516599A (ja) 2011-05-26
US8377941B2 (en) 2013-02-19
TW201004939A (en) 2010-02-01
AU2009237649A1 (en) 2009-10-22
ZA201006855B (en) 2011-06-29
IL208575A (en) 2014-04-30
IL208574A0 (en) 2010-12-30
BRPI0910585A2 (pt) 2015-09-22
CA2721630A1 (en) 2009-10-22
EA201071201A1 (ru) 2011-04-29
CL2009000916A1 (es) 2010-12-31
WO2009127678A1 (en) 2009-10-22
PE20091724A1 (es) 2009-12-06
CN102066356A (zh) 2011-05-18
EP2279183B1 (en) 2012-08-08
AU2009237650A1 (en) 2009-10-22
ES2392795T3 (es) 2012-12-13
MX2010011358A (es) 2010-11-10
CN102066357A (zh) 2011-05-18
US20110028486A1 (en) 2011-02-03
IL208575A0 (en) 2010-12-30
AR071203A1 (es) 2010-06-02
EP2279184A1 (en) 2011-02-02
BRPI0911682A2 (pt) 2015-10-13
MX2010011359A (es) 2010-11-12
EP2279184B1 (en) 2012-08-08
EP2279183A1 (en) 2011-02-02
US20110034515A1 (en) 2011-02-10
CA2725441A1 (en) 2009-10-22
US8283365B2 (en) 2012-10-09
KR20100135911A (ko) 2010-12-27
KR20100133016A (ko) 2010-12-20
AU2009237649B2 (en) 2012-07-26
ES2392796T3 (es) 2012-12-13
JP2011516598A (ja) 2011-05-26
ZA201006856B (en) 2011-06-29
IL208574A (en) 2014-04-30
CA2725441C (en) 2014-05-27
AU2009237650B2 (en) 2012-05-31
WO2009127679A1 (en) 2009-10-22
CN102066357B (zh) 2014-04-09
EA017726B1 (ru) 2013-02-28

Similar Documents

Publication Publication Date Title
UY31769A1 (es) Derivados del indol con actividad modulatoria del receptor nicotínico de acetilcolina
CR20110432A (es) Pirimidinas fusionadas
AU2011232516A8 (en) Chemical compounds
CR20120295A (es) Triazolopiridinas
UY33801A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
CY1119218T1 (el) Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp)
SV2009003349A (es) Compuestos triciclicos, composiciones y procedimientos
EA201190179A1 (ru) Способы и промежуточные химические соединения для получения фармацевтических средств
EA201270216A1 (ru) Фармацевтический состав
MA32938B1 (fr) Composes organiques
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
NZ612380A (en) Modulators of toll-like receptors
ES2661055T8 (es) Determinación de haplotipos de KIR por amplificación de exones
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
CY1113131T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
PH12013501628A1 (en) S1p modulating agents
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CR20120635A (es) Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
DOP2010000053A (es) Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno
AU2012213775A8 (en) 7-azaindole derivatives
CO6390029A2 (es) Polimorfos de (s)-3-amino-metil-7-(hidroxi-propoxi)-3h-benzo-[c][1,2]-oxaborol-1-ol
CR20130539A (es) Triazolopiridinas
CR20120637A (es) Triazolopiridinas sustituidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181025